Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Zoetis (ZTS) stock
Learn how to easily invest in Zoetis stock.
Zoetis Inc is a drug manufacturers-specialty & generic business based in the US. Zoetis shares (ZTS) are listed on the NYSE and all prices are listed in US Dollars. Zoetis employs 11,300 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Zoetis
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZTS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Zoetis stock price (NYSE: ZTS)Use our graph to track the performance of ZTS stocks over time.
Zoetis shares at a glance
|Latest market close||$175.20|
|52-week range||$141.02 - $201.78|
|50-day moving average||$188.87|
|200-day moving average||$169.34|
|Wall St. target price||$192.81|
|Dividend yield||$0.85 (0.43%)|
|Earnings per share (TTM)||$3.71|
Buy Zoetis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Zoetis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zoetis price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||-6.35%|
|3 months (2021-04-28)||2.03%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Is Zoetis under- or over-valued?
Valuing Zoetis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zoetis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zoetis's P/E ratio
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Zoetis shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's PEG ratio
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.5788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7 billion|
|Operating margin TTM||35.88%|
|Gross profit TTM||$4.6 billion|
|Return on assets TTM||12.42%|
|Return on equity TTM||51.75%|
|Market capitalisation||$95.2 billion|
TTM: trailing 12 months
Shorting Zoetis shares
There are currently 4.3 million Zoetis shares held short by investors – that's known as Zoetis's "short interest". This figure is 15.6% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.
Zoetis's "short interest ratio" (SIR)
Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 1.6 million). Zoetis's SIR currently stands at 2.62. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2620 shares are currently held short.
However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.009% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.
Find out more about how you can short Zoetis stock.
Zoetis's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Zoetis's total ESG risk score
Total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Zoetis's environmental score
Environmental score: 2.72/100
Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Zoetis's social score
Social score: 13/100
Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Zoetis's governance score
Governance score: 8.87/100
Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Zoetis's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||28.6|
|Total ESG percentile||49.38|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
Zoetis share dividends
Dividend payout ratio: 23.56% of net profits
Recently Zoetis has paid out, on average, around 23.56% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.5% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zoetis shareholders could enjoy a 0.5% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.85 per share.
While Zoetis's payout ratio might seem low, this can signify that Zoetis is investing more in its future growth.
Zoetis's most recent dividend payout was on 31 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 19 July 2021 (the "ex-dividend date").
Zoetis share price volatility
Over the last 12 months, Zoetis's shares have ranged in value from as little as $141.0212 up to $201.7846. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.6382. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists.
Stocks similar to Zoetis
Zoetis in the news
CORT or ZTS: Which Is the Better Value Stock Right Now?
Robust Valuation Leaves Neogen Little Room For Error After Mixed Results
Stocks That Hit 52-Week Highs On Friday
Frequently asked questionsWhat percentage of Zoetis is owned by insiders or institutions?
Currently 0.18% of Zoetis shares are held by insiders and 93.335% by institutions. How many people work for Zoetis?
Latest data suggests 11,300 work at Zoetis. When does the fiscal year end for Zoetis?
Zoetis's fiscal year ends in December. Where is Zoetis based?
Zoetis's address is: 10 Sylvan Way, Parsippany, NJ, United States, 07054 What is Zoetis's ISIN number?
Zoetis's international securities identification number is: US98978V1035 What is Zoetis's CUSIP number?
Zoetis's Committee on Uniform Securities Identification Procedures number is: 98978V103
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert